Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | PGD | P52209 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10002061 | 1.00 | TSHR (0.45) | TSHRPGDCYP2C9PDE4ATP53 | |
| SCHEMBL2616762 | 1.00 | TSHR (0.45) | TSHRPGDCYP2C9PDE4ATP53 | |
| SCHEMBL9609679 | 1.00 | TSHR (0.45) | TSHRPGDCYP2C9PDE4ATP53 | |
| SCHEMBL17693480 | 1.00 | TSHR (0.45) | TSHRPGDCYP2C9PDE4ATP53 | |
| SCHEMBL3453885 | 0.79 | TSHR (0.45) | TSHRPGDCYP2C9PDE4ATP53 | |
| SCHEMBL28150772 | 0.77 | TSHR (0.43) | TSHRPGDCYP2C9PDE4A | |
| SCHEMBL28163286 | 0.77 | TSHR (0.43) | TSHRPGDCYP2C9PDE4A | |
| SCHEMBL13017376 | 0.76 | — | — | |
| SCHEMBL13017377 | 0.76 | — | — | |
| SCHEMBL15859132 | 0.75 | TSHR (0.41) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230277500-A1 | COMPOSITIONS COMPRISING ATICAPRANT | Janssen Pharmaceuticals, Inc. | 2023-09-07 | — | — | US | disclosed |
| US-11739050-B2 | Method for purification of terpenoid amino alcohol derivatives | SCI PHARMTECH INC. (TW) | 2023-08-29 | — | — | US | disclosed |
| US-20180093981-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GENZYME CORPORATION | 2018-04-05 | — | — | US | disclosed |
| US-20170258802-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | GENZYME CORPORATION | 2017-09-14 | — | — | US | disclosed |
| US-9744153-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745294-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-20170210696-A1 | Process for the Preparation of Metaraminol | LABORATORI ALCHEMIA S.R.L. (IT) | 2017-07-27 | — | — | US | disclosed |
| US-20170151145-A1 | POWERFUL HAIR TREATMENT AGENT HAVING ANTI-WASHOUT EFFECT | HENKEL AG & CO. KGAA (DE) | 2017-06-01 | — | — | US | disclosed |
| US-20170151153-A1 | POWERFUL HAIR TREATMENT AGENT WITH ANTI-WASHOUT EFFECT | HENKEL AG & CO. KGAA (DE) | 2017-06-01 | — | — | US | disclosed |
| US-20170015620-A1 | PROCESS FOR THE PREPARATION OF EXAMETAZIME | JUBILANT DRAXIMAGE INC. (CA) | 2017-01-19 | — | — | US | disclosed |
| US-20120322787-A1 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120322786-A1 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2012-12-20 | — | — | US | disclosed |
| US-8309593-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120264787-A1 | Respiratory Disease Treatment | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2012-10-18 | — | — | US | disclosed |
| US-8236786-B2 | Respiratory disease treatment | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2012-08-07 | — | — | US | disclosed |
| US-20120136096-A1 | PROTECTION OF A DISPERSING AGENT DURING A GRINDING OPERATION | LAFARGE (FR) | 2012-05-31 | — | — | US | disclosed |
| US-20110184021-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GENZYME CORPORATION | 2011-07-28 | — | — | US | disclosed |
| US-20110166134-A1 | Glucosylceramide Synthase Inhibition For The Treatment Of Collapsing Glomerulopathy And Other Glomerular Disease | GENZYME CORPORATION | 2011-07-07 | — | — | US | disclosed |
| US-20110053945-A1 | SALTS OF 6-(5-CHLORO-2-PYRIDYL)-5-[(4-METHYL-1-PIPERAZINYL)CARBONYLOXY]-7-OXO-6,7-DIHY-DRO-5H-PYRROLO[3,4-B]PYRAZINE | SEPRACOR INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053986-A1 | RESPIRATORY DISEASE TREATMENT | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053945-A1 | SALTS OF 6-(5-CHLORO-2-PYRIDYL)-5-[(4-METHYL-1-PIPERAZINYL)CARBONYLOXY]-7-OXO-6,7-DIHY-DRO-5H-PYRROLO[3,4-B]PYRAZINE | MDH2, SLC25A11, MDH1 | TSHR 3075/4885PGD 80/4885CYP2C9 1405/4885 |
| US-20170151145-A1 | POWERFUL HAIR TREATMENT AGENT HAVING ANTI-WASHOUT EFFECT | OAT, HOGA1, LGALS7; LGALS7B | TSHR 2728/4885PGD 60/4885CYP2C9 4455/4885 |
| US-20110184021-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GBA1, GBA2, ASAH2 | TSHR 3687/4885PGD 412/4885CYP2C9 1928/4885 |
| US-20230277500-A1 | COMPOSITIONS COMPRISING ATICAPRANT | ADORA1, ADORA2B, ADORA2A | TSHR 4710/4885PGD 2506/4885CYP2C9 98/4885 |
| US-20120322786-A1 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, ASAH2 | TSHR 3687/4885PGD 412/4885CYP2C9 1928/4885 |
| US-11739050-B2 | Method for purification of terpenoid amino alcohol derivatives | ADH1A, MSMO1, MED1 | TSHR 3612/4885PGD 757/4885CYP2C9 1529/4885 |
| US-20170258802-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | SGMS1, SGMS2, CERS2 | TSHR 4238/4885PGD 1022/4885CYP2C9 4252/4885 |
| US-20170210696-A1 | Process for the Preparation of Metaraminol | MSMO1, METAP1, M6PR | TSHR 1821/4885PGD 684/4885CYP2C9 1061/4885 |
| US-20120322787-A1 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | ASAH2, GBA1, GAA | TSHR 2541/4885PGD 617/4885CYP2C9 3202/4885 |
| US-20110166134-A1 | Glucosylceramide Synthase Inhibition For The Treatment Of Collapsing Glomerulopathy And Other Glomerular Disease | GBA1, UGCG, GBA2 | TSHR 3985/4885PGD 451/4885CYP2C9 4539/4885 |
| US-20170151153-A1 | POWERFUL HAIR TREATMENT AGENT WITH ANTI-WASHOUT EFFECT | SLC25A13, HOGA1, GCDH | TSHR 2420/4885PGD 41/4885CYP2C9 4204/4885 |
| US-20120264787-A1 | Respiratory Disease Treatment | IL5, PPARD, PPARG | TSHR 832/4885PGD 176/4885CYP2C9 789/4885 |
| US-20170015620-A1 | PROCESS FOR THE PREPARATION OF EXAMETAZIME | CUL5, SAMM50, ADRM1 | TSHR 878/4885PGD 2648/4885CYP2C9 1180/4885 |
| US-20180093981-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | ASAH2, GBA1, GAA | TSHR 2541/4885PGD 617/4885CYP2C9 3202/4885 |
| US-20110053986-A1 | RESPIRATORY DISEASE TREATMENT | IL5, PPARD, PPARG | TSHR 832/4885PGD 176/4885CYP2C9 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.